title: Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
abstract: Cytosine arabinoside (ara-C) is one of the most active compounds in the treatment of acute leukemias. In the majority of current protocols ara-C is combined with other cytotoxic agents in an attempt to increase antileukemic activity. The present study investigated the impact of etoposide, teniposide, amsacrine, mitoxantrone, anthracyclines, and asparaginase on the cellular accumulation of ara-C and its intracellular metabolism in order to provide a better rationale for combination therapy. Intracellular accumulation and phosphorylation of ara-C were determined in peripheral blast cells from twenty patients with acute leukemias after exposure to 1 and 10 mumol/l ara-C alone and after preincubation with 1 and 10 micrograms/ml etoposide, 10 and 100 micrograms/ml teniposide, 10 mumol/l amsacrine, 500 ng/ml mitoxantrone (or daunorubicin or doxorubicin) or 10 mumol/l asparaginase. Ara-C accumulation at 10 mumol/l was decreased by 1 microgram/ml etoposide (67 +/- 18% of control), 10 micrograms/ml etoposide (30 +/- 22%), 10 micrograms/ml teniposide (12 +/- 23%), 100 micrograms/ml teniposide (10 +/- 18%), and amsacrine (51 +/- 21%). Intracellular ara-CTP formation was determined at an extracellular concentration of 10 mumol/l and preincubation with these drugs. The intracellular formation of ara-CTP was decreased by 1 microgram/ml etoposide (77 +/- 15% of control), 10 micrograms/ml etoposide (32 +/- 22%), 10 micrograms/ml teniposide (10 +/- 9%), 100 micrograms/ml teniposide (0 +/- 0%), but not by amsacrine. These data indicate that prior exposure to etoposide and teniposide influence ara-C metabolism and possibly cytotoxicity, and thus should not immediately precede ara-C administration in clinical trials.
authors.affiliation: Medizinische Universitätsklinik und Poliklinik, Innere Medizin II, Tübingen, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: B
authors.initials: B
authors.lastname: Proksch
authors.forename: T
authors.initials: T
authors.lastname: Wanner
authors.forename: U
authors.initials: U
authors.lastname: Schuler
authors.forename: F W
authors.initials: FW
authors.lastname: Busch
authors.forename: H
authors.initials: H
authors.lastname: Schmidt
authors.forename: E
authors.initials: E
authors.lastname: Schleyer
authors.forename: K
authors.initials: K
authors.lastname: Jaschonek
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000677:Amsacrine / Q000494:pharmacology; D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism*; D003561:Cytarabine / Q000378:metabolism / Q000493:pharmacokinetics*; D004347:Drug Interactions; D005047:Etoposide / Q000494:pharmacology*; D006801:Humans; D007938:Leukemia / Q000378:metabolism* / Q000473:pathology; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology; D010766:Phosphorylation; D013713:Teniposide / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000378:metabolism / Q000473:pathology
chemical_list: D000677:Amsacrine; D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate; D005047:Etoposide; D013713:Teniposide